Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (DE:1YG)
FRANKFURT:1YG
Immunicum AB (1YG) Stock Price & Analysis
1 Followers
1YG Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.00 - €0.12
Previous Close€0.02
Volume0.00
Average Volume (3M)N/A
Market Cap
€39.56M
Enterprise Value€37.08M
Total Cash (Recent Filing)kr55.40M
Total Debt (Recent Filing)kr26.49M
Price to Earnings (P/E)N/A
Beta-0.59
Next Earnings
May 17, 2024EPS Estimate
>-€0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding863,148,371
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
1YG FAQ
What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was €0.00 and its highest was €0.12 in the past 12 months.
What is Immunicum AB’s market cap?
Currently, no data Available
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s upcoming earnings report date is May 17, 2024 which is in 8 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on Feb 14, 2024. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.
Is Immunicum AB overvalued?
According to Wall Street analysts Immunicum AB’s price is currently Overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate is >-€0.01.
How many shares outstanding does Immunicum AB have?
Currently, no data Available
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in DE:1YG
---
Immunicum AB Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Company Description
Immunicum AB
Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors. The company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum's business currently consists of research and development for the production of pharmaceuticals.
---
Technical Analysis
---